S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:ACOR

Acorda Therapeutics - ACOR Stock Forecast, Price & News

$0.47
+0.01 (+2.18%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.45
$0.48
50-Day Range
$0.31
$0.64
52-Week Range
$0.28
$4.99
Volume
97,028 shs
Average Volume
259,681 shs
Market Capitalization
$6.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ACOR stock logo

About Acorda Therapeutics (NASDAQ:ACOR) Stock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Acorda Therapeutics in a research report on Tuesday, August 9th. They set a "hold" rating on the stock.

Acorda Therapeutics Stock Up 1.5 %

NASDAQ:ACOR opened at $0.47 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The stock's 50 day moving average is $0.46 and its two-hundred day moving average is $1.13. Acorda Therapeutics has a 1-year low of $0.28 and a 1-year high of $4.99.

Acorda Therapeutics (NASDAQ:ACOR - Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($1.93) earnings per share for the quarter. The company had revenue of $22.53 million for the quarter. Acorda Therapeutics had a negative net margin of 98.25% and a negative return on equity of 90.29%. As a group, equities analysts expect that Acorda Therapeutics will post -0.96 EPS for the current year.

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

Acorda Therapeutics Misses Q2 EPS by $2.79
Acorda Therapeutics Inc Stock Quote ACOR
Why Acorda Therapeutics Shares Gaining Today?
Esteve Launches INBRIJA® in Germany
Acorda Therapeutics, Inc. Provides Notice of Data Privacy Event
Acorda Therapeutics, Inc. (ACOR)
Acorda Therapeutics Q4 Earnings Preview
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Company Calendar

Last Earnings
11/09/2021
Today
8/14/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
118
Year Founded
1995

Profitability

Net Income
$-103,950,000.00
Pretax Margin
-76.60%

Debt

Sales & Book Value

Annual Sales
$129.07 million
Book Value
$6.62 per share

Miscellaneous

Free Float
12,768,000
Market Cap
$6.22 million
Optionable
Optionable
Beta
0.46

Social Links


Key Executives

  • Dr. Ron Cohen M.D. (Age 66)
    Founder, CEO, Pres & Director
    Comp: $1.21M
  • Ms. Lauren M. Sabella (Age 61)
    Chief Operating Officer
    Comp: $740.7k
  • Dr. Burkhard Blank M.D. (Age 67)
    Interim Head of Drug Safety
    Comp: $1.36M
  • Mr. Michael A. Gesser M.B.A. (Age 59)
    Chief Financial Officer
  • Mr. Robert Morales (Age 54)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller
  • Ms. Felicia Vonella
    VP of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 62)
    Gen. Counsel
  • Ms. Tierney Saccavino
    Exec. VP of Corp. Communications
  • Ms. Denise J. Duca
    Exec. VP of HR
  • Mr. Kerry M. Clem (Age 52)
    Chief Commercial Officer













ACOR Stock - Frequently Asked Questions

How have ACOR shares performed in 2022?

Acorda Therapeutics' stock was trading at $2.39 at the beginning of the year. Since then, ACOR shares have decreased by 80.4% and is now trading at $0.4680.
View the best growth stocks for 2022 here
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ACOR earnings forecast
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.43) EPS for the quarter, topping the consensus estimate of ($1.56) by $0.13. The biopharmaceutical company earned $31.46 million during the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 90.29% and a negative net margin of 98.25%.

When did Acorda Therapeutics' stock split?

Shares of Acorda Therapeutics reverse split before market open on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 31st 2020. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (6.78%), Virtu Financial LLC (1.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jane Wasman and Ron Cohen.
View institutional ownership trends
.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $0.47.

How much money does Acorda Therapeutics make?

Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $6.22 million and generates $129.07 million in revenue each year. The biopharmaceutical company earns $-103,950,000.00 in net income (profit) each year or ($8.87) on an earnings per share basis.

How many employees does Acorda Therapeutics have?

The company employs 118 workers across the globe.

When was Acorda Therapeutics founded?

Acorda Therapeutics was founded in 1995.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.

This page (NASDAQ:ACOR) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.